Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TATTON: AZD9291 in Combination With Novel Therapeutics in EGFRm+ Advanced NSCLC
NCT02143466Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2014
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of osimertinib, savolitinib, selumetinib and durvalumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by AstraZeneca. Primary endpoint: Number of participants with Adverse Events and/or Dose Limiting Toxicities. Started Aug 2014; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02143466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02143466.